Chinese Small-Molecule Biotech Zelgen Bio Completes RMB 600 Million Series C Round Ahead of Hong Kong IPO Filing

Jan 12, 2026 11:11 CST Updated 11:11

Zenitar

Innovative Drug R&D and Industrialization Service Provider

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoringShow: Zenitar Completes Nearly 600 Million RMB in Series C Financing. This round of financingCo-led by Temasek's wholly-owned subsidiary, Temming Capital, and Qiming Venture PartnersTencent Investment, BlueRun Ventures, Xiamen C&D Emerging Investment, and Shanghai Science and Technology Innovation Fund participated in the investment; existing shareholders including FiveSource Capital, Cowin Capital, Guosheng Capital, and Sichuan Science and Technology Investment Group continued to support.

The funds from this round of financing will be mainly used to support global clinical research and development, expansion of the R&D pipeline, and upgrading of the technology platform.

Specifically, including, 1,Global Clinical DevelopmentAccelerate the advancement of two hematology/oncology drug candidates with global competitiveness, which are in Phase III registrational stage, expand their clinical development for other indications, and initiate overseas clinical trials for multiple immunology/inflammation and central nervous system drug candidates to establish an international market presence; secondly,R&D Pipeline Expansion. By expanding the indications of existing varieties and advancing the differentiated molecular design of new targets in parallel, continuously enriching and upgrading the innovative drug pipeline; three,Technology Platform UpgradeContinuously strengthen the collaborative capabilities of the three core technology platforms, systematically enhancing the entire drug R&D chain based on ZeniFold with profound structural biology analysis capabilities, ZeniMind driven by AI for drug discovery and design, and ZeniScreen for clinically relevant disease screening models.

References:

PharmaCircle Data;

Moxie Pharma pharma.bcpmdata.com (formerly known as Yaoke Rongyun Data);

; etc.